

GUIDING CLINICAL DECISION-MAKING IN ADVANCED *EGFR*- MUTANT NSCLC

THURSDAY
21 MARCH 2024
13:30-15:00 CET

FORUM HALL,
PRAGUE CONGRESS CENTRE,
PRAGUE, CZECH REPUBLIC

Join us at ELCC 2024 for an exciting, interactive symposium held both in-person and livestreamed for optimal experience

SCIENTIFIC COMMITTEE



Martin Reck
Germany



Umberto Malapelle
Italy

LEARNING OBJECTIVES

After attending this symposium, participants should be able to:

- Review the current treatment landscape for *EGFR*-mutant NSCLC and discuss how this may evolve in the future
- Gain expert insights on the practical management of patients with *EGFR*-mutant NSCLC in routine clinical practice

PROGRAM

SESSION	SPEAKERS
Welcome and introductions	Martin Reck
Guiding treatment decision choices: Molecular pathology in <i>EGFR</i> -mutant NSCLC	Umberto Malapelle
Navigating the current treatment landscape for common <i>EGFR</i> -mutant NSCLC	Raffaele Califano, Jordi Remon
Discussion	All faculty
Advances in <i>EGFR</i> exon20ins mutations in NSCLC	Pascale Tomasini
Discussion	All faculty
Living with lung cancer: Implementing shared decision-making with our patients	Martin Reck, Petra Adamková
Closing remarks	Umberto Malapelle